Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (71-80 of 356) with videos related to

Pageof 36
Sort By:
Expert Opinion on Investigational Drugs|November 29, 2021
COVID-related fibrosis: insights into potential drug targetsGiacomo Sgalla, Alessia Comes, Marialessia Lerede, et al.
Clinics in Chest Medicine|May 24, 2021
Progress and Innovation in Interstitial Lung DiseaseKerri A Johannson, Harold R Collard, Luca Richeldi
Expert Opinion on Emerging Drugs|March 18, 2011
Emerging drugs for idiopathic pulmonary fibrosisMoisés Selman, Annie Pardo, Luca Richeldi, et al.
Clinics in Chest Medicine|February 28, 2012
Interstitial lung diseases. PrefaceTalmadge E King, Harold R Collard, Luca Richeldi
The European Respiratory Journal|September 2, 2015
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthroughGabriel Thabut, Bruno Crestani, Raphaël Porcher, et al.
Journal of Medical Case Reports|July 9, 2016
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case reportStefania Cerri, Giacomo Sgalla, Luca Richeldi, et al.
Expert Review of Respiratory Medicine|December 12, 2018
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosisRiccardo Inchingolo, Francesco Varone, Giacomo Sgalla, et al.
International Archives of Occupational and Environmental Health|December 14, 2006
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patientAlberto Franchi, Luca Richeldi, Giovanni Parrinello, et al.
Thorax|July 31, 2010
Unexpected identification of bilateral masses in an asymptomatic heavy smokerElisa Garlassi, Giulio Rossi, Andrea Bedini, et al.
Lancet (London, England)|April 3, 2017
Idiopathic pulmonary fibrosisLuca Richeldi, Harold R Collard, Mark G Jones
Pageof 36

Showing results (71-80 of 356) with videos related to

Sort By:
Pageof 36
Expert Opinion on Investigational Drugs|November 29, 2021
COVID-related fibrosis: insights into potential drug targetsGiacomo Sgalla, Alessia Comes, Marialessia Lerede, et al.
Clinics in Chest Medicine|May 24, 2021
Progress and Innovation in Interstitial Lung DiseaseKerri A Johannson, Harold R Collard, Luca Richeldi
Expert Opinion on Emerging Drugs|March 18, 2011
Emerging drugs for idiopathic pulmonary fibrosisMoisés Selman, Annie Pardo, Luca Richeldi, et al.
Clinics in Chest Medicine|February 28, 2012
Interstitial lung diseases. PrefaceTalmadge E King, Harold R Collard, Luca Richeldi
The European Respiratory Journal|September 2, 2015
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthroughGabriel Thabut, Bruno Crestani, Raphaël Porcher, et al.
Journal of Medical Case Reports|July 9, 2016
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case reportStefania Cerri, Giacomo Sgalla, Luca Richeldi, et al.
Expert Review of Respiratory Medicine|December 12, 2018
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosisRiccardo Inchingolo, Francesco Varone, Giacomo Sgalla, et al.
International Archives of Occupational and Environmental Health|December 14, 2006
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patientAlberto Franchi, Luca Richeldi, Giovanni Parrinello, et al.
Thorax|July 31, 2010
Unexpected identification of bilateral masses in an asymptomatic heavy smokerElisa Garlassi, Giulio Rossi, Andrea Bedini, et al.
Lancet (London, England)|April 3, 2017
Idiopathic pulmonary fibrosisLuca Richeldi, Harold R Collard, Mark G Jones
Pageof 36